ArticleTranslational vision science & technology2025
Altered Neuroretinal Tissue in Childhood Cancer Survivors: Data From the German CVSS Study.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study reports on alterations of the peripapillary retinal nerve fiber layer (pRNFL) in long-term childhood cancer survivors (CCS) for the first time. Methods: In the Cardiac and Vascular Late Sequelae in Long-Term Survivors of Childhood Cancer-Study (CVSS), a cross-sectional study, 1002 CCS (aged 23-48 years) diagnosed with neoplasia before the age of 15 years were prospectively enrolled in an ophthalmological examination including pRNFL-measurements with spectral-domain optical coherence tomography. An age- and sex-matched sample of the population-based Gutenberg Health Study (GHS) served as the comparison group. Differences in pRNFL in CCS with cancer types and treatments were explored. Results: Four hundred forty-nine CCS had pRNFL imaging and were included with a mean follow-up of 28.9 years. The pRNFL was 3.38 µm thinner in CCS compared with the GHS controls (P < 0.0001). The pRNFL was thinner in CCS with central nervous system tumors (P < 0.001), leukemia (P < 0.001), renal tumors (P = 0.004), neuroblastoma (P < 0.001), soft-tissue sarcoma (P = 0.003), and malignant bone tumor (P = 0.004), but not different after lymphoma and germ cell tumor. Treatment with platin derivates (P = 0.02) and cranial radiation (P = 0.02) were negatively associated with pRNFL. Subgroup analysis revealed a thinner pRNFL in leukemia CCS and treatment with anthracyclines (P < 0.001) and methotrexate (P = 0.01). No association was found for ifosfamide, vinca alkaloids, asparaginase chemotherapy, and cardiac radiation. Conclusions: The pRNFL is thinner in CCS with most common tumor entities, except lymphoma and germ cell tumors. Cranial radiation and platin derivates had negative effects on the pRNFL thickness. Translational Relevance: Follow-ups are needed to evaluate if this might result in increased risk for neurodegenerative ophthalmic diseases, like glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.